Effects of ospemifene on drug metabolism mediated by cytochrome P450 enzymes in humans in vitro and in vivo

International Journal of Molecular Sciences

Volumn 14, Issue 7, 2013, Pages 14064-14075

  Turpeinen, Miia ^a   Uusitalo, Jouko ^b   Lehtinen, Terhi ^c   Kailajärvi, Marita ^c   Pelkonen, Olavi ^a   Vuorinen, Jouni ^d   Tapanainen, Pasi ^e   Stjernschantz, Camilla ^f   Lammintausta, Risto ^f   Scheinin, Mika ^c  

^a UNIVERSITY OF OULU   (Finland)

^b Technopolis Oyj   (Finland)

^c Institute of Biomedicine   (Finland)

^d Pharma   (Finland)

^e Vitabalans Ltd   (Finland)

^f Hormos Medical Ltd   (Finland)

Author keywords

Bupropion; CYP; Omeprazole; Selective estrogen receptor modulator; Warfarin

Indexed keywords

4 HYDROXYOSPEMIFENE; 4' HYDROXYOSPEMIFENE; AMFEBUTAMONE; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DRUG METABOLITE; ESTROGEN RECEPTOR; OMEPRAZOLE; OSPEMIFENE; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER MICROSOME; MAXIMUM PLASMA CONCENTRATION; PHASE 1 CLINICAL TRIAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY TRACT INFECTION;

AGED; ANTI-ULCER AGENTS; ANTICOAGULANTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTINEOPLASTIC AGENTS, HORMONAL; AREA UNDER CURVE; BUPROPION; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HEPATOCYTES; HUMANS; MICROSOMES, LIVER; MIDDLE AGED; OMEPRAZOLE; TAMOXIFEN; WARFARIN;

EID: 84880144679     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140714064     Document Type: Article

References (19)

1. Bachmann, G.A.; Komi, J.O.; The Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: Results from a pivotal phase 3 study. Menopause 2010, 17, 480-486.
2. McCall, J.L.; DeGregorio, M.W. Pharmacologic evaluation of ospemifene. Expert Opin. Drug Metab. Toxicol. 2010, 6, 773-779.
3. Komi, J.; Lankinen, K.S.; Härkönen, P.; DeGregorio, M.W.; Voipio, S.; Kivinen, S.; Tuimala, R.; Vihtamäki, T.; Vihko, K.; Ylikorkala, O., et al. Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women. Menopause 2005, 12, 202-209.
4. Rutanen, E.M.; Heikkinen, J.; Halonen, K.; Komi, J.; Lammintausta, R.; Ylikorkala, O. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: A double-blind, randomized trial. Menopause 2003, 10, 433-439.
5. Simon, J.A.; Lin, V.H.; Radovich, C.; Bachmann, G.A.; The Ospemifene Study Group. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 2013, 20, 418-427.
6. Portman, D.J.; Bachmann, G.A.; Simon, J.A.; The Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013, 20, 623-630.
7. Morello, K.C.; Wurz, G.T.; DeGregorio, M.W. Pharmacokinetics of selective estrogen receptor modulators. Clin. Pharmacokinet. 2003, 42, 361-372.
8. Tolonen, A.; Koskimies, P.; Turpeinen, M.; Uusitalo, J.; Lammintausta, R.; Pelkonen, O. Ospemifene metabolism in humans in vitro and in vivo: Metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol. Drug Interact. 2013, 14, 1-9.
9. Koskimies, P.; Turunen, J.; Lammintausta, R.; Scheinin, M. Single-dose and steady-state pharmacokinetics of ospemifene, a selective estrogen receptor modulator, in postmenopausal women. Int. J. Clin. Pharm. 2013, Accepted for publication.
10. Pelkonen, O.; Turpeinen, M.; Hakkola, J.; Honkakoski, P.; Hukkanen, J.; Raunio, H. Inhibition and induction of human cytochrome P450 enzymes: Current status. Arch. Toxicol. 2008, 82, 667-715.
11. European Medicines Agency, Committee for Human Medicinal Products (CHMP). Guideline on the investigation of drug interactions, CPMP/EWP/560/95. Available online: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf (accessed on 26 June 2013).
12. Givens, C.B.; Bullock, L.N.; Franks, A.S. Safety of concomitant tamoxifen and warfarin. Ann. Pharmacother. 2009, 43, 1867-1871.
13. Fareston (toremifene citrate) Label 2011. GTx, Inc. Available online: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020497s006lbl.pdf (accessed on 3 July 2013).
14. Evista (raloxifene hydrochloride) Label 2007. Eli Lilly & Company. Available online: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022042lbl.pdf (accessed on 3 July 2013).
15. Miller, J.W.; Skerjanec, A.; Knadler, M.P.; Ghosh, A.; Allerheiligen, S.R. Divergent effects of raloxifene HCI on the pharmacokinetics and pharmacodynamics of warfarin. Pharm. Res. 2001, 18, 1024-1028.
16. Turpeinen, M.; Ghiciuc, C.; Opritoui, M.; Tursas, L.; Pelkonen, O.; Pasanen, M. Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: A comparative study in vitro. Xenobiotica 2007, 37, 1367-1377.
17. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
18. Turpeinen, M.; Uusitalo, J.; Jalonen, J.; Pelkonen, O. Multiple P450 substrates in a single run: Rapid and comprehensive in vitro interaction assay. Eur. J. Pharm. Sci. 2005, 24, 123-132.
19. Tolonen, A.; Petsalo, A.; Turpeinen, M.; Uusitalo, J.; Pelkonen, O. In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: Analytical validation and testing with monoclonal anti-CYP antibodies. J. Mass. Spectrom. 2007, 42, 960-966.